Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599
The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration with Insilico Medicine to predict disease...
Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026...
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico's first FTD, recognizing the clinical potential in advanced mesothelioma. ISM6331 is a novel, potential best-in-class, pan-TEAD...
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma...
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class, brain-penetrant, non-opioid solution for pain management. Superior Therapeutic Profile: In...
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 15, 2026 /PRNewswire/ -- Insilico...
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 13, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an...
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months...
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature...
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug...